Published in J Immunol Res on August 25, 2015
Toll-like Receptors in the Vascular System: Sensing the Dangers Within. Pharmacol Rev (2016) 0.84
CpG-ODN Shapes Alum Adjuvant Activity Signaling via MyD88 and IL-10. Front Immunol (2017) 0.75
The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol (2010) 24.08
Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity (2011) 11.15
Toll-like receptors control activation of adaptive immune responses. Nat Immunol (2001) 7.54
Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling. Science (2006) 6.47
Control of B-cell responses by Toll-like receptors. Nature (2005) 6.44
Toll-dependent selection of microbial antigens for presentation by dendritic cells. Nature (2006) 5.54
The vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4. Science (2007) 4.90
Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med (2006) 3.25
AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J Immunol (2009) 2.49
TLR-based immune adjuvants. Vaccine (2010) 2.10
Suppression of asthma-like responses in different mouse strains by oral tolerance. Am J Respir Cell Mol Biol (2001) 1.95
Toll-like receptor 4 agonists adsorbed to aluminium hydroxide adjuvant attenuate ovalbumin-specific allergic airway disease: role of MyD88 adaptor molecule and interleukin-12/interferon-gamma axis. Clin Exp Allergy (2008) 1.83
(How) do aluminium adjuvants work? Immunol Lett (2005) 1.53
Bacterial lipopolysaccharide signaling through Toll-like receptor 4 suppresses asthma-like responses via nitric oxide synthase 2 activity. J Immunol (2003) 1.46
Sensing of microbial molecular patterns by Toll-like receptors. Immunol Rev (2012) 1.39
Unleashing the potential of NOD- and Toll-like agonists as vaccine adjuvants. Proc Natl Acad Sci U S A (2014) 1.36
TLR ligands can activate dendritic cells to provide a MyD88-dependent negative signal for Th2 cell development. J Immunol (2005) 1.27
Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann N Y Acad Sci (1995) 1.22
Immunostimulatory activity of haptenated proteins. Proc Natl Acad Sci U S A (2009) 1.10
High doses of CpG oligodeoxynucleotides stimulate a tolerogenic TLR9-TRIF pathway. Nat Commun (2013) 1.03
Vaccine renaissance. Nat Rev Microbiol (2007) 1.01
Getting closer to the dirty little secret. Immunity (2011) 0.95
IFN-alpha inhibits antigen-induced eosinophil and CD4+ T cell recruitment into tissue. J Immunol (1994) 0.94
Effect of inactivated poliovirus vaccine on the antibody response to Bordetella pertussis antigens when combined with diphtheria-pertussis-tetanus vaccine. Clin Infect Dis (1996) 0.92
Modulation of B cell responses by Toll-like receptors. Cell Tissue Res (2010) 0.92
Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics. Curr Pharm Des (2010) 0.92
Use and limitations of alum-based models of allergy. Clin Exp Allergy (2008) 0.87
Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant. J Immunol (2014) 0.86
Antigenic competition in a multivalent foot rot vaccine. Vaccine (1994) 0.86
The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol (2013) 0.86
Unconventional strategies for the suppression of allergic asthma. Curr Drug Targets Inflamm Allergy (2003) 0.80
Challenges in the development, licensure, and use of combination vaccines. Clin Infect Dis (2001) 0.80
Homeostatic inflammation in innate immunity. Curr Opin Immunol (2014) 0.79
Issues in design of clinical trials of combination vaccines. Ann N Y Acad Sci (1995) 0.77
Anaphylaxis to DPT vaccine. J R Soc Med (1985) 0.77